PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

  • PAVmed established an interesting hub and spoke business model with joint services and selling stakes in commercially ready technologies.
  • This opens up new financing streams and potentially a lot of value creation for PAVmed shareholders.
  • But near-term, the viability depends on things going right for Lucid, which is not guaranteed.
  • Still, given the potential, we think PAVM is cheap enough for a speculative position.
  • Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More »

PAVmed: Lots Of Potential But EsoGuard Determines Short-Term Progress